Tag: Gastroesophageal junction cancer

ALX Oncology’s evorpacept gets FDA ODD for gastric cancer and gastroesophageal junction cancer

pallavi123- January 30, 2022

ALX Oncology said that its CD47 blocker evorpacept has secured orphan drug designation (ODD) from the US Food and Drug Administration (FDA) in gastric cancer ... Read More

Leap Therapeutics gets FDA orphan status for DKN-01 for gastric and gastroesophageal junction cancer

pharmanewsdaily- June 12, 2020

US immuno-oncology company Leap Therapeutics has been granted orphan drug designation for DKN-01 from the US Food and Drug Administration (FDA) for the treatment of ... Read More

Five Prime, Zai Lab initiate phase 3 trial of bemarituzumab chemo combo

pharmanewsdaily- October 1, 2018

Five Prime Therapeutics and Zai Lab have dosed the first patient in a phase 3 study of bemarituzumab (FPA144) in combination with chemotherapy in patients ... Read More